Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

Slides:

Advertisements

Similar presentations

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.

Advertisements

Increased Plasma Indoleamine 2,3-Dioxygenase Activity and Interferon-γ Levels Correlate with the Severity of Acute Graft-versus-Host Disease after Allogeneic.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell.

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Paul Szabolcs, Donna Niedzwiecki

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Outcomes of Unrelated Umbilical Cord Blood Transplantation for X-Linked Adrenoleukodystrophy Donald Beam, Michele D. Poe, James M. Provenzale, Paul Szabolcs,

Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus- Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after.

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Statistical Considerations in Studies of Late Effects in HCT

Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease Caron A. Jacobson, Lixian Sun, Haesook.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

What is quality in a transplant program?

Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine- Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias Zachariah McIver,

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Blood and Marrow Transplant Handbook

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R

Mammen Chandy Biology of Blood and Marrow Transplantation

Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria Madan Jagasia, Jennifer Giglia, Wichai.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van Dorp, Floor Pietersma, Matthias Wölfl, Leo F. Verdonck, Eefke J. Petersen, Henk M. Lokhorst, Edwin Martens, Matthias Theobald, Debbie van Baarle, Ellen Meijer, Jürgen Kuball Biology of Blood and Marrow Transplantation Volume 15, Issue 6, Pages 671-678 (June 2009) DOI: 10.1016/j.bbmt.2009.02.005 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 B cell counts pre- and post-RICT in patients who received (white bars) and did not receive (black bars) Rtx within 6 months prior to RICT compared to a healthy control group (gray bar). Statistical analyses compare B cell counts of patients of each time point to B cell counts of the healthy control group. Counts before RICT (within 1 week), or months after RICT are indicated. Bars indicate median and range. Numbers indicate the number of samples measured per time point. Only significant changes (P < .05) are indicated. Statistical analyses were performed with a Mann-Whitney U-test. Biology of Blood and Marrow Transplantation 2009 15, 671-678DOI: (10.1016/j.bbmt.2009.02.005) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 1-Kaplan-Meier curves of aGVHD grade II-IV (A) and grade III-IV (B) in patients who received Rtx prior to RICT and in patients who did not. (C) Onset of aGVHD grade III-IV in patients who received Rtx prior to RICT and in patients who did not. Biology of Blood and Marrow Transplantation 2009 15, 671-678DOI: (10.1016/j.bbmt.2009.02.005) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 1-Kaplan-Meier curves of total cGVHD (A) extensive cGVHD (B), and limited cGVHD (C) in patients who received Rtx prior to RICT and in patients who did not. Biology of Blood and Marrow Transplantation 2009 15, 671-678DOI: (10.1016/j.bbmt.2009.02.005) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Kaplan-Meier curves of PFS (A) and OS (B) in patients who received Rtx prior to RICT and in patients who did not. Biology of Blood and Marrow Transplantation 2009 15, 671-678DOI: (10.1016/j.bbmt.2009.02.005) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions